FindTrial
Sign In

Usage of Dapagliflozin in the management of Type-2 Diabetes Mellitus in Indian patients

Usage of Dapagliflozin - a Sodium Glucose Co-transporter inhibitor, in the management of Type-2 Diabetes Mellitus: A Real world evidence study in Indian patients - FOREFRONT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/03/008011
Enrollment
2000
Registered
2017-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Type 2 Diabetes

Interventions

Intervention1: Non-Interventional study: There is no intervention in the study, this is purely non-interventional study

Sponsors

AstraZeneca Pharma India Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who provide written informed consent. 2. Patients with previously diagnosed Type-2 diabetes mellitus 3. Patients with inadequately controlled diabetes (HbA1c >7%) with existing anti-diabetic medications, prior to initiation of dapagliflozin treatment. 4. Patients who are taking dapagliflozin within last 3 months. 5.Patients who are having past medical records for demographic information, weight, blood pressure and HbA1c value at the time of dapagliflozin prescribed

Exclusion criteria

Exclusion criteria: 1.Patients with Type-1 diabetes mellitus 2. Patients with any medical condition which in the opinion of the investigator would interfere with safe completion of the study 3. Pregnant or lactating women

Design outcomes

Primary

MeasureTime frame
Mean change in HbA1CTimepoint: 6 month—

Secondary

MeasureTime frame
Mean change in weight and BPTimepoint: 6 month—

Countries

India

Contacts

Public ContactAmit Kumar

AstraZeneca Pharma India Ltd

Hardik.Vasnawala@astrazeneca.com9902097245

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026